A subsidiary of Biocon Limited i.e. Biocon Biologics and Mylan, a subsidiary of Viatris Inc., have received a positive opinion from European Medicines Agency's committee for medicinal products for human use (CHMP), recommending approval of the market authorisation of Kixelle, a biosimilar Insulin Aspart, which is rapid-acting insulin for the treatment of type 1 and 2 diabetes.

KEC International Ltd, a flagship company of RPG Enterprises, informed that it has received new orders worth Rs 1,438 crore. This order is divided into various businesses namely railways, civil, transmission & distribution as well as cables.

United States Food & Drug Administration (USFDA) has issued the first emergency use authorisation (EUA) as a vaccine for COVID-19.

UPL: UPL has denied a report appearing in certain sections of the media that SEBI has initiated a forensic audit with respect to the whistle-blower complaint. UPL is asking SEBI to inquire about this and similar malicious reporting in the last few months.

In the last week, volatility was witnessed on the Indian shores, especially in the last trading session of the week as the market swung both ways before settling the day with modest gains. The extinct bears had attempted all tricks in the books to make a comeback but all efforts were in vain as the mighty bulls were backed by the strong liquidity gush by FIIs.

Going ahead, the opening on Monday and the price action thereafter is crucial to watch out for as sustaining & closing below 13,400 would be a breach of the rising trendline on the 75-minutes chart and long-legged Doji gets a confirmation. Hence, for Monday, 13,400 would be crucial for the bulls as a close below this would let the bears put a foot into the door.

The shares of Indian Hume Pipe Company Ltd were trading up by 4 per cent on Friday after the company informed the bourses that it has bagged a Rs 550 crore order in Uttar Pradesh, India.

The stock of Shipping Corporation of India Limited has given a downward sloping trendline breakout as of November 26, 2020, and thereafter, witnessed a nearly 63 per cent upward move in just 11 trading sessions. However, on Friday, the stock formed a reversal dark cloud cover candlestick pattern, which signals a possible trend reversal.

The stock's relative strength index (RSI) has reached its highest value in the last 14 weeks, which is bullish. It has also managed to close above the 60 mark after a span of almost seven months.

Pharma major, Alembic Pharmaceuticals Limited informed the exchanges on Friday that it has received approval from United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Asenapine sublingual tablets, 5 mg & 10 mg.